Back to Urology
Urologyv1982Evidence-Based

Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma

Provides prognostic grading system for clear cell renal cell carcinoma (RCC) based on nuclear morphology and cellular appearance. Independent predictor of cancer-specific survival that correlates nuclear grade with prognosis.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
fuhrman grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within urology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Grading based on nuclear diameter, shape, nucleoli visibility, and presence of bizarre features. Grade 1-3 determined by worst feature among the first three parameters. Grade 4 if bizarre/multilobed nuclei or spindle cells present.

Clinical Pearls & Practice Notes

  • Grade is assigned based on the highest grade features present in the tumor
  • The WHO/ISUP grading system is now recommended over Fuhrman grading for better prognostic accuracy
  • Nuclear grade is one of the most important prognostic factors in renal cell carcinoma
  • Most tumors are grades 2-3; grade 1 is rare (<5%), grade 4 accounts for 5-10%
  • Higher grades correlate with worse cancer-specific survival

Evidence & Literature Citations

  1. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655-63. doi: 10.1097/00000478-198210000-00007.
  2. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, Ficarra V, Cindolo L, de la Taille A, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer. 2007 Mar 1;109(5):868-74. doi: 10.1002/cncr.22463.
  3. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb.

Score Interpretation Ranges

Grade 11 – 1 pts

Small nuclei, round and uniform

Grade 22 – 2 pts

Slightly irregular nuclei with visible nucleoli

Grade 33 – 3 pts

Obviously irregular nuclei with prominent nucleoli

Grade 44 – 4 pts

Pleomorphic nuclei with extreme features

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.